Abstract
Tumors with c-ros oncogene 1 (ROS1) translocations are a newly discovered molecular subset of non esmall-cell lung cancer (NSCLC). Like anaplastic lymphoma receptor tyrosine kinase (ALK)-rearranged NSCLC, early phase clinical trials show a high response rate to crizotinib in these patients. Some retrospective studies suggest patients with ALKP tumorshave a longer progression-free survival (PFS) to pemetrexed compared with other chemotherapeutics- though this is controversial. Little is known about whether patients with ROS1-rearranged tumors preferentially respond to specific chemotherapy drugs. This small, retrospective case series suggests that some NSCLC patients whose tumors harbor the ROS1 gene rearrangements might have a lengthy PFS using pemetrexed-containing therapy. In clinical practice, oncologists might want to consider pemetrexed-containing regimens when chemotherapy is indicated.
Original language | English |
---|---|
Pages (from-to) | 592-595 |
Number of pages | 4 |
Journal | Clinical Lung Cancer |
Volume | 14 |
Issue number | 5 |
DOIs | |
State | Published - Sep 2013 |
Externally published | Yes |
Keywords
- Chemotherapy
- Molecular subtypes
- NSCLC
- Pemetrexed
- ROS1